Budde, Holger

[["dc.bibliographiccitation.firstpage","1127"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","1133"],["dc.bibliographiccitation.volume","96"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Papert, Susanne"],["dc.contributor.author","Maas, Jens-Holger"],["dc.contributor.author","Reichardt, Holger Michael"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T10:22:22Z"],["dc.date.available","2018-11-07T10:22:22Z"],["dc.date.issued","2017"],["dc.description.abstract","Graft-versus-host disease (GvHD) still belongs to the major challenges after allogeneic hematopoietic stem cell transplantation (HSCT). Immune-suppressive therapy against GvHD is a double-edged sword due to risk of infections and relapse. The ability to adapt prophylactic treatment according to the probability of severe GvHD would be an essential advantage for the patients. We analyzed different biomarkers for their potential to predict the development of GvHD in 28 patients who underwent allogeneic HSCT. Blood was taken once directly after hematopoietic engraftment. In this study, patients were monitored for 12 months after HSCT for the occurrence of acute GvHD or acute/chronic GvHD overlap syndrome. Soluble IL-2 receptor and CD4/CD8 T cell ratio were independently associated with the occurrence of GvHD in the observation period. However, the largest area under the receiver operating characteristic curve with 0.90 was observed when a 5-parameter biomarker score based on CD4(+) T cells, CD8(+) T cells, CD19(-) CD21(+) precursor B cells, CD4/CD8 T cell ratio, and soluble IL-2 receptor was used to predict GvHD. In addition, CD8(+) T cell levels above 2.3% of all mononuclear cells after engraftment may predict relapse-free survival at least for 12 months. In summary, we found a new biomarker panel for prediction of GvHD which is featured by established laboratory assays and high statistical significance. In order to introduce the biomarker panel into routine clinical protocols, we suggest performing a larger multi-center study."],["dc.identifier.doi","10.1007/s00277-017-2999-5"],["dc.identifier.isi","000403078900008"],["dc.identifier.pmid","28447161"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42255"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.relation.issn","1432-0584"],["dc.relation.issn","0939-5555"],["dc.title","Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","58"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Perfusion"],["dc.bibliographiccitation.lastpage","66"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Vormfelde, Steffen"],["dc.contributor.author","Tirilomis, Theodor"],["dc.contributor.author","Friedrich, Martin G."],["dc.date.accessioned","2020-12-10T18:38:24Z"],["dc.date.available","2020-12-10T18:38:24Z"],["dc.date.issued","2019-01"],["dc.description.abstract","Background: Re-transfusion of autologous blood is an important aspect of intraoperative blood management. Hemolysis and platelet dysfunction due to turbulence in the blood suction system strongly impede later usage of suction blood for re-transfusion. The aim of this study was to analyze the effects of a novel surgical-blood suction system with an automatic control setup for minimization of turbulence in the blood flow. Methods: We compared the turbulence-controlled suction system (TCSS) with a conventional suction system and untreated control blood in vitro. Blood cell counts, hemolysis levels according to free hemoglobin (fHb) and platelet function were analyzed to determine the integrity of the suction blood. Results: In the conventional suction system, we found a strong increase of the fHb levels. In contrast, erythrocyte integrity was almost completely preserved when using the TCSS. We obtained similar results regarding platelet function. The expression of platelet glycoproteins, such as GP IIb/IIIa and P-selectin, native or after stimulation with ADP, were markedly impaired by the conventional system, but not by the TCSS. In addition, platelet aggregometry revealed significant platelet dysfunction in conventional suction blood, but less aggregation impairments were present in blood samples from the TCSS. Conclusion: Our findings on an in vitro assessment show major improvements in red blood cell integrity and platelet function of suction blood when using the TCSS compared to a conventional suction system. These results reflect a significant benefit for autologous re-transfusion. We suggest testing the TCSS in surgery for clinical evaluation."],["dc.identifier.doi","10.1177/0267659118790915"],["dc.identifier.eissn","1477-111X"],["dc.identifier.issn","0267-6591"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77305"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.publisher","SAGE Publications"],["dc.relation.eissn","1477-111X"],["dc.relation.issn","0267-6591"],["dc.title","The effect of a novel turbulence-controlled suction system in the prevention of hemolysis and platelet dysfunction in autologous surgery blood"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","HLA"],["dc.bibliographiccitation.volume","89"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Papert, Susanne"],["dc.contributor.author","Reichardt, Holger Michael"],["dc.contributor.author","Jarry, Hubertus"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T10:23:29Z"],["dc.date.available","2018-11-07T10:23:29Z"],["dc.date.issued","2017"],["dc.format.extent","345"],["dc.identifier.isi","000400973300016"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42465"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Wiley"],["dc.publisher.place","Hoboken"],["dc.relation.issn","2059-2310"],["dc.relation.issn","2059-2302"],["dc.title","AN ALTERNATIVE SETUP FOR EXTRACORPOREAL PHOTOPHERESIS: 8-METHOXYPSORALEN AND UVA-TREATED LEUKOCYTES FROM ALLOGENEIC DONORS IMPROVE GRAFT VERSUS HOST DISEASE IN MICE"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","HLA"],["dc.bibliographiccitation.volume","89"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Papert, Susanne"],["dc.contributor.author","Maas, Jens-Holger"],["dc.contributor.author","Reichardt, Holger Michael"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T10:23:29Z"],["dc.date.available","2018-11-07T10:23:29Z"],["dc.date.issued","2017"],["dc.format.extent","362"],["dc.identifier.isi","000400973300051"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42466"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Wiley"],["dc.publisher.place","Hoboken"],["dc.relation.issn","2059-2310"],["dc.relation.issn","2059-2302"],["dc.title","SCREENING FOR A BIOMARKER PANEL FOR PREDICTION OF GRAFT VERSUS HOST DISEASE IN HUMANS"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","465"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","472"],["dc.bibliographiccitation.volume","95"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Sorns, Marie-Sophie"],["dc.contributor.author","Welker, Pia"],["dc.contributor.author","Licha, Kai"],["dc.contributor.author","Wolff, Hendrik"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T10:18:30Z"],["dc.date.available","2018-11-07T10:18:30Z"],["dc.date.issued","2016"],["dc.description.abstract","Graft-versus-host disease (GvHD) is a severe immune reaction commonly occurring after hematopoietic stem cell transplantation. The outcome of patients who do not respond to the currently used immunosuppressive drugs is poor, thus there is an urgent need for the evaluation of new therapies. Heparin has a well-known anti-inflammatory effect and heparin analogues with a low anticoagulant effect are interesting candidates as new anti-inflammatory drugs. We explored the therapeutic potential of dendritic polyglycerol sulfates (dPGS), a novel class of heparin derivatives, on murine acute GvHD in vivo. The therapeutic effect of dPGS on murine GvHD was more intense after intravenous application compared to subcutaneous injection. An increased survival rate and improved clinical scores were observed in mice treated with 5 mg/kg once a week. In these animals, there was a reduction in the percentage of CD4(+) and CD8(+) T cells, which are the main effectors of GvHD. In addition, dPGS treatment decreased the number of tumor necrosis factor alpha (TNF alpha)-producing T cells. Increasing the dose of dPGS reversed the positive effect on survival as well as the clinical score, which indicates a small therapeutic range. Here, we report for the first time that dPGS have a significant immunosuppressive in vivo effect in a mouse model of severe acute GvHD. Therefore, we propose to study dPGS as promising candidates for the development of potential new drugs in the treatment of steroid-refractory GvHD patients first in larger animals and later in humans."],["dc.identifier.doi","10.1007/s00277-015-2565-y"],["dc.identifier.isi","000371605300013"],["dc.identifier.pmid","26634847"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41459"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1432-0584"],["dc.relation.issn","0939-5555"],["dc.title","Dendritic polyglycerol sulfate attenuates murine graft-versus-host disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1073"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Nucleosides, Nucleotides & Nucleic Acids"],["dc.bibliographiccitation.lastpage","1081"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Rau, Anne Lone"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias J."],["dc.date.accessioned","2020-12-10T18:15:14Z"],["dc.date.available","2020-12-10T18:15:14Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1080/15257770.2020.1755042"],["dc.identifier.eissn","1532-2335"],["dc.identifier.issn","1525-7770"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/74785"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Apoptosis induction by miR-19b inhibition: does it show therapeutic potential for leukemia?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e105896"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Kolb, Susanne"],["dc.contributor.author","Tejedor, Laura Salinas"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Reichardt, Holger Michael"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T09:36:27Z"],["dc.date.available","2018-11-07T09:36:27Z"],["dc.date.issued","2014"],["dc.description.abstract","Background: Graft-versus-host disease (GvHD) is a major challenge after hematopoietic stem cell transplantation but treatment options for patients are still limited. In many cases first-line treatment with glucocorticoids is not successful. Among second-line therapies the extracorporeal photopheresis (ECP) is frequently performed, due to induction of selective tolerance instead of general immunosuppression. However, for some patients with severe acute GvHD the leukapheresis step of the ECP procedure is physically exhausting and limits the number of ECP cycles. Methods: We hypothesized that leukocytes from healthy cell donors could be used as a replacement for ECP leukocytes gained from the GvHD patient. For this purpose we used a well established mouse model of acute GvHD. The ECP therapy was based on cells with the genetic background of the initial donor of the stem cell transplantation. As a precondition we developed a protocol representing conventional ECP in mice equivalent to clinical used ECP setup. Results: We could demonstrate that conventional, clinically derived ECP setup is able to alleviate acute GvHD. By using leukocytes obtained from healthy mice with the bone marrow donor's genetic background we could not observe a statistically significant therapeutic effect. Conclusions: Conventional human ECP setup is effective in the mouse model of severe acute GvHD. In addition we could not prove that ECP cells from healthy mice with bone marrow donor's genetic background are as effective as ECP cells derived from GvHD mice. Based on our findings, new questions arise for further studies, in which the cellular characteristics for ECP mediated immune tolerance are a matter of investigation."],["dc.description.sponsorship","Deutsche Jose Carreras Leukamie Stiftung e.V [DJCLS R 12/34]"],["dc.identifier.doi","10.1371/journal.pone.0105896"],["dc.identifier.isi","000341230600094"],["dc.identifier.pmid","25148404"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10790"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32622"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Public Library Science"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Modified Extracorporeal Photopheresis with Cells from a Healthy Donor for Acute Graft-versus-Host Disease in a Mouse Model"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Central European Journal of Immunology"],["dc.bibliographiccitation.lastpage","9"],["dc.bibliographiccitation.volume","42"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Berntsch, Ulrike"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T10:28:37Z"],["dc.date.available","2018-11-07T10:28:37Z"],["dc.date.issued","2017"],["dc.description.abstract","Extracorporeal photopheresis (ECP) is an important second-line therapy for graft-versus-host disease. A central therapeutic mechanism is the induction of immune tolerance through apoptosis in patient's leukocytes, caused by ex vivo incubation with 8-methoxypsoralen (8-MOP) and subsequent UVA irradiation. We hypothesized that different 8-MOP incubation times and an additional 8-MOP removal step could influence the apoptosis kinetics of leukocytes in general and in particular could lead to different apoptotic levels in the leukocyte subpopulations. After 8-MOP/UVA treatment of human leukocytes, cells were cultured and the percentage of annexin V positive cells from several leukocyte subpopulations was determined. Only regulatory T cells (Tregs) were relatively resistant to 8-MOP/UVA induced apoptosis. When cells were incubated for 30 minutes with 8-MOP prior to UVA exposure, higher percentages of annexin V positive cells were detected on day 1 and day 2 after treatment. Removal of 8-MOP after UVA exposure caused no significant changes in the apoptosis kinetics during the 72 h culture period compared with unwashed cells. The results of our in vitro study indicate that it could be possible to adjust the apoptosis kinetics via modulation of the 8-MOP incubation time. In further in vivo studies it should be elucidated to which extent different apoptosis kinetics influence the therapeutic effect of ECP since steady-state apoptosis levels are probably important for establishing a long lasting immune tolerance. Furthermore we found that Tregs, according to their well-known tolerogenic function, are more resistant to apoptosis after 8-MOP/UVA treatment compared to GvHD inducing T cell populations."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2017"],["dc.identifier.doi","10.5114/ceji.2017.67312"],["dc.identifier.isi","000401601400001"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14479"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43462"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Termedia Publishing House Ltd"],["dc.relation.issn","1644-4124"],["dc.relation.issn","1426-3912"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","In vitro effects of different 8-methoxypsoralen treatment protocols for extracorporeal photopheresis on mononuclear cells"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","632"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Haematologica"],["dc.bibliographiccitation.lastpage","638"],["dc.bibliographiccitation.volume","104"],["dc.contributor.author","Dauber, Eva-Maria"],["dc.contributor.author","Mayr, Wolfgang R."],["dc.contributor.author","Hustinx, Hein"],["dc.contributor.author","Schönbacher, Marlies"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Legler, Tobias J."],["dc.contributor.author","König, Margit"],["dc.contributor.author","Haas, Oskar A."],["dc.contributor.author","Fritsch, Gerhard"],["dc.contributor.author","Körmöczi, Günther F."],["dc.date.accessioned","2020-12-10T18:44:18Z"],["dc.date.available","2020-12-10T18:44:18Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.3324/haematol.2018.201293"],["dc.identifier.eissn","1592-8721"],["dc.identifier.issn","0390-6078"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78401"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Somatic mosaicisms of chromosome 1 at two different stages of ontogenetic development detected by Rh blood group discrepancies"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","803"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Vox Sanguinis"],["dc.bibliographiccitation.lastpage","810"],["dc.bibliographiccitation.volume","113"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Papert, Susanne"],["dc.contributor.author","Reichardt, Holger M."],["dc.contributor.author","Jarry, Hubertus"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias J."],["dc.date.accessioned","2020-12-10T18:36:32Z"],["dc.date.available","2020-12-10T18:36:32Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1111/vox.12723"],["dc.identifier.issn","0042-9007"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76662"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","An alternative for extracorporeal photopheresis: 8-methoxypsoralen and UVA-treated leucocytes from allogeneic donors improve graft-versus-host disease in mice"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]